Business Wire India

(21st October, 2014; Business Wire India); GVK Biosciences (GVK BIO) – Asia’s leading integrated Discovery Research and Development organization today announced the successful completion of in-silico based alternative indications of shelved compounds for Takeda Pharmaceutical Company Limited using GVK BIO’s proprietary Drug Repurposing Platform. Taking the project to the next level, GVK BIO and Takeda have jointly agreed to evaluate the pre-clinical proof-of-concept for certain indications of selected therapeutic compounds to develop novel indications for the previously failed compounds.

(6th October, 2014; Business Wire India); Galderma, a global healthcare company focused on dermatology, today announced that it has initiated a Phase II clinical trial of a novel muscle relaxant in the United States. The study is investigating the safety and efficacy of Galderma’s internally developed liquid formulation of botulinum toxin in the setting of aesthetic dermatology and cosmetic surgery and will add to the existing Galderma neurotoxin franchise.

(30th September, 2014; Business Wire India); Apollo Hospitals and Sanofi today announced their decision to collaborate on the expansion of Apollo Sugar Clinics, which provide integrated diabetes care programs in India. Through this collaboration, Apollo and Sanofi plan to leverage their respective expertise in diabetes to provide patients with access to comprehensive educational resources, treatment and care programs that can help patients better manage their diabetes. The first wave of this collaboration will focus on the establishment of 50 Apollo Sugar Clinics.

(30th September, 2014; Business Wire India); For the Maharashtra government, addressing health issues ranks high on its list of priorities and the same is reflected through various policy interventions, innovative steps and strategies implemented to provide quality healthcare for all.

(30th September, 2014; Business Wire India); Fortis Healthcare announced on last friday (26th sept) that Fortis Mulund, one of its major hospitals in Mumbai has been conferred the prestigious British Medical Journal (BMJ) Award for ‘The Medical Team of the Year 2014.’ The honour was bestowed on the hospital for its outstanding “Antibiotic Review Program – and Antibiotic Restriction Policy.”

(30th September, 2014; Business Wire India); Fortis Healthcare has been awarded the prestigious 2014 ‘Porter Prize, for Value Based Healthcare’. The prize was given in recognition of the company’s outstanding performance in the industry and for redefining the idea of patient care and fundamentally challenging the economic models within the industry.

(20th September, 2014; Business Wire India); Boehringer Ingelheim obtains exclusive global rights for development and commercialisation of CureVac’s investigational therapeutic cancer vaccine CV9202CV9202 is based on CureVac’s mRNA technology (RNActive®) Clinical investigation of CV9202 will be initiated in at least two different lung cancer treatment settings, in combination with Boehringer Ingelheim’s afatinib* and in the chemo-radiation setting. The in-licensing of this investigational cancer compound adds a highly innovative new approach to Boehringer Ingelheim’s lung cancer development portfolio.

International SOS continues to provide expert advice to client organisations during the ongoing Ebola outbreak. This outbreak is unprecedented in its magnitude, multi-country spread, and impact on health services and economies.

(9th September, 2014; Business Wire India); In its endeavour to build awareness and consciousness Apollo  Hospitals in association with ISQua, JCI, NABH and many other institutions hosted the 4th International Congress on Patient Safety along with the 5th edition of International Conference on Transforming Healthcare with IT 2014 for the first time in the Eastern part of the country. The two day event took place on 5th and 6th of September, 2014 at ITC Sonar, Kolkata.